Philip Bath

Last updated

Philip Bath

FRCP FMedSci
Born (1956-10-07) 7 October 1956 (age 66)
Venezuela
NationalityBritish
Education GKT School of Medical Education
Occupation(s)Stroke physician, clinical researcher, academic
Medical career
Institutions
Sub-specialties
Research

Philip Michael Bath FRCP FMedSci (born 7 October 1956) is a British clinician scientist. He is Stroke Association Professor of Stroke Medicine at the Stroke Trials Unit within the University of Nottingham. He specialises clinically in stroke and academically has established large-scale trials in treating and preventing stroke. Bath worked as a junior doctor before specialising in general medicine, stroke and hypertension. He is an Honorary Consultant Physician at Nottingham University Hospitals NHS Trust. He has spent his academic career at St George's, University of London, King's College London and University of Nottingham.

Contents

Early life and education

Bath was educated at Dulwich College in London, U.K. and studied medicine at St Thomas's Hospital Medical School, now GKT School of Medical Education. graduating with a Bachelor of Science (BSc) degree in Physiology in 1979, and Bachelor of Medicine, Bachelor of Surgery (MB BS) in 1982. He undertook research for a Doctor of Medicine (M.D.) degree, completing it in 1992 and winning the Rogers prize at University of London. His thesis was titled "Human monocyte behaviour and interactions with endothelium : aspects of physiology and pathology". [1] He was awarded his Doctor of Science (D.Sc.) from the University of Nottingham in 2015, entitled "Management of blood pressure after stroke". [2]

Career

Having worked as a junior doctor, Bath specialised in internal medicine. In 1986 he became a Member of the Royal Colleges of Physicians of the United Kingdom (MRCP), and in 1998 a Fellow of the Royal College of Physicians (FRCP). From 1991 to 1993, Bath was a lecturer at the Blood Pressure Unit at St George's, University of London where he worked for the distinguished hypertensionologist, Professor Graham MacGregor. He moved in 1993 to King's College Hospital Medical School, London, now GKT School of Medical Education as Senior Lecturer, and Honorary Consultant Physician at King's College Hospital where he established the Acute Stroke Unit. In 1998, he moved to the University of Nottingham as Stroke Association Professor of Stroke Medicine, and Head of the Division of Stroke Medicine. [3] His Division was integrated into the Division of Clinical Neuroscience, [4] in 2013, which he headed until 2021. He is an Honorary Consultant Physician at Nottingham University Hospitals NHS Trust where he works in Stroke/TIA outpatient department.

Research

Bath is recognised as an expert in stroke and clinical trials. His current research is focused on the hyperacute treatment and prevention of stroke. As a Clinical Trialist, he has been Chief Investigator of five phase III/IV trials: TAIST, [5] ENOS, [6] STEPS, [7] TARDIS, [8] and RIGHT-2. [9] He is Chief Investigator of the ongoing National Institute for Health Research (NIHR) HTA-funded Pharyngeal Electrical stimulation for Acute Stroke dysphagia Trial (PhEAST). [10]

Honours

In 2016 Bath was elected a Fellow of the Academy of Medical Sciences (FMedSci) [11] and appointed as Senior Investigator at the NIHR. [12] He is a Fellow of the European Stroke Organisation (2005) and American Heart Association (2014). He gave the Stroke Association keynote lecture in 2015. [13] He received the Feinberg Award for Excellence in Clinical Stroke from the American Heart Association in 2016, [14] the President's Award from the British Association of Stroke Physicians (BASP) in 2019, [15] the President's Award from the World Stroke Organization (WSO) in 2021, [16] and the President's Award from the European Stroke Organisation (ESO) in 2023. [17]

Related Research Articles

<span class="mw-page-title-main">Aspirin</span> Medication

Aspirin, also known as acetylsalicylic acid (ASA), is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain, fever, and/or inflammation, and as an antithrombotic. Specific inflammatory conditions which aspirin is used to treat include Kawasaki disease, pericarditis, and rheumatic fever.

<span class="mw-page-title-main">Heart Protection Study</span>

The Heart Protection Study was a randomized controlled trial run by the Clinical Trial Service Unit, and funded by the Medical Research Council (MRC) and the British Heart Foundation (BHF) in the United Kingdom. It studied the use of the cholesterol lowering drug, simvastatin 40 mg and vitamin supplementation in people who were at risk of cardiovascular disease. It was led by Jane Armitage, an epidemiologist at the Clinical Trial Service Unit.

<span class="mw-page-title-main">Stroke</span> Death of a region of brain cells due to poor blood flow

A stroke is a medical condition in which poor blood flow to the brain causes cell death. There are two main types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding. Both cause parts of the brain to stop functioning properly.

<span class="mw-page-title-main">Thromboxane</span> Group of lipids

Thromboxane is a member of the family of lipids known as eicosanoids. The two major thromboxanes are thromboxane A2 and thromboxane B2. The distinguishing feature of thromboxanes is a 6-membered ether-containing ring.

<span class="mw-page-title-main">Carotid artery stenosis</span> Medical condition

Carotid artery stenosis is a narrowing or constriction of any part of the carotid arteries, usually caused by atherosclerosis.

<span class="mw-page-title-main">Paul Ridker</span> Cardiovascular epidemiologist and biomedical researcher

Paul M. Ridker is a cardiovascular epidemiologist and biomedical researcher. He is currently the Eugene Braunwald Professor of Medicine at Harvard University and Brigham and Women's Hospital, where he directs the Center for Cardiovascular Disease Prevention. Ridker also holds an appointment as Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health.

Sir Rory Edwards Collins FMedSci FRS is a British physician who is Professor of Medicine and Epidemiology at the Clinical Trial Service Unit within the University of Oxford, the head of the Nuffield Department of Population Health and a Fellow of Green Templeton College, Oxford. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer, while also being closely involved in developing approaches to the combination of results from related studies ("meta-analyses"). Since September 2005, he has been the Principal Investigator and Chief Executive of the UK Biobank, a prospective study of 500,000 British people aged 40–69 at recruitment.

<span class="mw-page-title-main">Ticagrelor</span> Coronary medication

Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y12 receptor. The drug is produced by AstraZeneca.

The International Studies of Infarct Survival (ISIS) were four randomized controlled trials of several drugs for treating suspected acute myocardial infarction. More than 134,000 patients from over 20 countries took part in four large simple trials between 1981 and 1993, coordinated from Oxford, England.

The management of atrial fibrillation (AF) is focused on preventing temporary circulatory instability, stroke and other ischemic events. Control of heart rate and rhythm are principally used to achieve the former, while anticoagulation may be employed to decrease the risk of stroke. Within the context of stroke, the discipline may be referred to as stroke prevention in atrial fibrillation (SPAF). In emergencies, when circulatory collapse is imminent due to uncontrolled rapid heart rate, immediate cardioversion may be indicated.

<span class="mw-page-title-main">Alimuddin Zumla</span> British-Zambian physician

Sir Alimuddin Zumla,, FRCP, FRCPath, FRSB is a British-Zambian professor of infectious diseases and international health at University College London Medical School. He specialises in infectious and tropical diseases, clinical immunology, and internal medicine, with a special interest in HIV/AIDS, respiratory infections, and diseases of poverty. He is known for his leadership of infectious/tropical diseases research and capacity development activities. He was awarded a Knighthood in the 2017 Queens Birthday Honours list for services to public health and protection from infectious disease. In 2012, he was awarded Zambia's highest civilian honour, the Order of the Grand Commander of Distinguished services - First Division. In 2022, for the fifth consecutive year, Zumla was recognised by Clarivate Analytics, Web of Science as one of the world's top 1% most cited researchers. In 2021 Sir Zumla was elected as Fellow of The World Academy of Sciences.

Professor Peter Sleight M.D.(Cantab.), D.M. (Oxon.) FRCP FACC was a distinguished and internationally renowned research cardiologist and an Honorary Consultant Physician at the John Radcliffe Hospital in Oxford and the Oxford University Hospitals NHS Foundation Trust. Sleight was Emeritus Field Marshal Alexander Professor of Cardiovascular Medicine at the University of Oxford and an Emeritus Fellow of Exeter College, Oxford.

Philip Warren Majerus was an American biochemist who confirmed the cardiovascular benefits of aspirin. After graduating from medical school and completing a residency at Massachusetts General Hospital, Majerus conducted research at the National Heart Institute before becoming a faculty member at the Washington University School of Medicine.

Joanna Marguerite Wardlaw is a Scottish physician, radiologist, and academic specialising in neuroradiology and pathophysiology. Wardlaw worked as a junior doctor before specialising as a radiologist. She continues to practice medicine as an Honorary Consultant Neuroradiologist with NHS Lothian. She has spent her entire academic career at the University of Edinburgh.

Elad I. Levy is an American neurosurgeon, researcher, and innovator who played a major role in the development and testing of thrombectomy, which improved quality of life and survival of stroke patients. He has focused his career and research on developing evidence based medicine and literature showing the benefits of thrombectomy for the treatment of stroke. He is currently Professor of Neurosurgery and Radiology, and the L. Nelson Hopkins, MD Professor Endowed Chair of the Department of Neurosurgery at the State University of New York at Buffalo (SUNY).

Colin Baigent is a British academic physician and cardiovascular epidemiologist. He is a Professor of Epidemiology, Director of the Medical Research Council Population Health Research Unit at the University of Oxford, and Deputy Director of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), part of Oxford Population Health. His work is focused in the design and coordination of large-scale randomised trials and the use of meta-analysis to assess the efficacy and safety of drugs for the prevention of cardiovascular disease (CVD) or premature death.

<span class="mw-page-title-main">RECOVERY Trial</span> Test of existing medicines on COVID-19

The Randomised Evaluation of COVID-19 Therapy is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. The trial was later expanded to Indonesia, Nepal and Vietnam. The trial has tested ten interventions on adults: eight repurposed drugs, one newly developed drug and convalescent plasma.

Sir Martin Jonathan Landray is a British physician, epidemiologist and data scientist who serves as a Professor of Medicine & Epidemiology at the University of Oxford. Landray designs, conducts and analyses large-scale randomised control trials; including practice-changing international trials that have recruited over 100,000 individuals. Landray previously led the health informatics team that enabled the collection and management of data for the UK Biobank on over half a million people.

Eleanor Barnes is a British physician at the John Radcliffe Hospital and a Professor of Hepatology and Experimental Medicine at the University of Oxford. She has studied hepatitis C and the development of the development of HCV vaccines. She is a Fellow of the Academy of Medical Sciences and serves as the lead for hepatology at the National Institute for Health Research (NIHR) Clinical Research Network.

<span class="mw-page-title-main">Lucy Chappell</span> British obstetrician and gynaecologist, researcher and chief executive officer

Lucy Chappell is a British professor of obstetrics at King’s College London and the Chief Scientific Adviser (CSA) for the UK Department of Health and Social Care. As part of her CSA role, she oversees the National Institute for Health and Care Research (NIHR) as Chief Executive Officer. Her research areas include medical problems during pregnancy such as pre-eclampsia, and the safety of medicines in pregnancy.

References

  1. ↑ Bath, Philip M.W. (1991). Human monocyte behaviour and interactions with endothelium : aspects of physiology and pathology (Ph.D).
  2. ↑ Bath, Philip M. (2015). "Management of blood pressure after stroke". OCLC   1252181237.{{cite journal}}: Cite journal requires |journal= (help)
  3. ↑ "Stroke".
  4. ↑ "Division of Clinical Neuroscience".
  5. ↑ Bath, Philip MW; Lindenstrom, Ewa; Boysen, Gudrun; De Deyn, Peter; Friis, Pal; Leys, Didier; Marttila, Reijo; Olsson, Jan-Edwin; O'Neill, Desmond; Orgogozo, Jean-Marc; Ringelstein, Bernd; Van Der Sande, Jan-Jacob; Turpie, Alexander GG (2001). "Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial". The Lancet. 358 (9283): 702–710. doi:10.1016/S0140-6736(01)05837-8. PMID   11551576. S2CID   40842062.
  6. ↑ ENOS Trial Investigators (2015). "Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial". The Lancet. 385 (9968): 617–628. doi:10.1016/S0140-6736(14)61121-1. PMC   4343308 . PMID   25465108.
  7. ↑ Bath, Philip M; Scutt, Polly; Love, Jo; Clave, Pere; Cohen, David; Dziewas, Rainer; Iversen, Helle K; Ledl, Christian; Ragab, Suzanne; Soda, Hassan; Warusevitane, Anushka; Woisard, Virginie; Hamdy, Shaheen (2016). "Pharyngeal electrical stimulation for treatment of dysphagia in subacute stroke: A randomized controlled trial". Stroke. 47 (6): 1562–1570. doi:10.1161/STROKEAHA.115.012455. PMC   4878285 . PMID   27165955.
  8. ↑ Bath, Philip M.; et al. (2018). "Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial". The Lancet. 391 (10123): 850–859. doi:10.1016/S0140-6736(17)32849-0. PMC   5854459 . PMID   29274727.
  9. ↑ Bath, Philip M.; et al. (2019). "Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial". The Lancet. 393 (10175): 1009–1020. doi:10.1016/S0140-6736(19)30194-1. PMC   6497986 . PMID   30738649.
  10. ↑ "Pharyngeal Electrical stimulation for Acute Stroke dysphagia Trial (PhEAST)".
  11. ↑ "Academy of Medical Sciences".
  12. ↑ "Professor Philip Bath reappointed as NIHR Senior Investigator - The University of Nottingham". www.nottingham.ac.uk. Retrieved 5 January 2022.
  13. ↑ "Wither the brain after stroke - acute treatment and prevention".
  14. ↑ Bath, Philip M. (2016). "High Explosive Treatment for Ultra-Acute Stroke: Hype or Hope". Stroke. 47 (9): 2423–2426. doi: 10.1161/strokeaha.116.013243 . PMID   27444258. S2CID   9105240.
  15. ↑ "British & Irish Association of Stroke Physicians".
  16. ↑ "World Stroke Organisation".
  17. ↑ "European Stroke Organisation Presidential Award".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.